ABSTRACT Inhibition of the ubiquitous serine peptidase dipeptidyl peptidase IV (DP IV) has attracted much recent attention as a potential therapeutic strategy in the treatment of diabetes. By protecting the full length, biologically active forms of a number of gut peptides, specific DP IV-inhibitors indirectly stimulate multiple hormonal axes effecting enhance β-cell growth, function, and survival as well as improved insulin sensitivity and glucose tolerance. The following provides a synopsis of our own studies examining the effects of long-term DP IV-inhibitor treatment in animal models of diabetes, and the relevance of these findings towards the treatment of type-1 and type-2 diabetes mellitus.
Buy this Article
|